BR112019008656A2 - composto de aminopirazolopirimidina usado como inibidor de receptor de tirosina quinase de fator neurotrófico - Google Patents

composto de aminopirazolopirimidina usado como inibidor de receptor de tirosina quinase de fator neurotrófico

Info

Publication number
BR112019008656A2
BR112019008656A2 BR112019008656A BR112019008656A BR112019008656A2 BR 112019008656 A2 BR112019008656 A2 BR 112019008656A2 BR 112019008656 A BR112019008656 A BR 112019008656A BR 112019008656 A BR112019008656 A BR 112019008656A BR 112019008656 A2 BR112019008656 A2 BR 112019008656A2
Authority
BR
Brazil
Prior art keywords
tyrosine kinase
aminopyrazopyrimidine
kinase receptor
neurotrophic factor
receptor inhibitor
Prior art date
Application number
BR112019008656A
Other languages
English (en)
Other versions
BR112019008656A8 (pt
Inventor
Kong Fansheng
Luo Hong
Xu Hongjiang
Zhu Li
Dai Liguang
Yang Ling
Guo Meng
Wang Shanchun
Wu Wei
Duan Xiaowei
Yang Yanqing
Sun Yinghui
Peng Yong
Han Yongxin
Hu Yuandong
Zhong Zhaobai
Original Assignee
Centaurus Biopharma Co Ltd
Chia Tai Tianqing Pharmaceutical Group Co Ltd
Lianyungang Runzhong Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Centaurus Biopharma Co Ltd, Chia Tai Tianqing Pharmaceutical Group Co Ltd, Lianyungang Runzhong Pharmaceutical Co Ltd filed Critical Centaurus Biopharma Co Ltd
Publication of BR112019008656A2 publication Critical patent/BR112019008656A2/pt
Publication of BR112019008656A8 publication Critical patent/BR112019008656A8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

é fornecido um composto de aminopirazolopirimidina conforme representado pela seguinte fórmula estrutural usada como um inibidor de receptor de tirosina quinase de fator neurotrófico. o composto pode inibir a atividade de trk quinase e pode tratar doenças mediadas por um receptor de trk tirosina quinase em mamíferos.
BR112019008656A 2016-10-28 2017-10-27 Composto de aminopirazolopirimidina usado como inibidor de receptor de tirosina quinase de fator neurotrófico BR112019008656A8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN201610970314 2016-10-28
CN201710044000 2017-01-21
PCT/CN2017/108100 WO2018077246A1 (zh) 2016-10-28 2017-10-27 用作神经营养因子酪氨酸激酶受体抑制剂的氨基吡唑并嘧啶化合物

Publications (2)

Publication Number Publication Date
BR112019008656A2 true BR112019008656A2 (pt) 2019-07-09
BR112019008656A8 BR112019008656A8 (pt) 2022-06-07

Family

ID=62024344

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112019008656A BR112019008656A8 (pt) 2016-10-28 2017-10-27 Composto de aminopirazolopirimidina usado como inibidor de receptor de tirosina quinase de fator neurotrófico

Country Status (16)

Country Link
US (1) US10829492B2 (pt)
EP (1) EP3533796B1 (pt)
JP (1) JP7046940B2 (pt)
KR (1) KR102616249B1 (pt)
CN (1) CN109890820B (pt)
AU (1) AU2017348826B2 (pt)
BR (1) BR112019008656A8 (pt)
CA (1) CA3041942C (pt)
DK (1) DK3533796T3 (pt)
ES (1) ES2896943T3 (pt)
HU (1) HUE057733T2 (pt)
MX (1) MX2019004847A (pt)
PL (1) PL3533796T3 (pt)
PT (1) PT3533796T (pt)
RU (1) RU2764523C2 (pt)
WO (1) WO2018077246A1 (pt)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113735881A (zh) * 2017-08-23 2021-12-03 正大天晴药业集团股份有限公司 含有氨基吡唑并嘧啶的大环化合物及其药物组合物和用途
CN108794370A (zh) * 2018-07-31 2018-11-13 上海弈柯莱生物医药科技有限公司 一种拉罗替尼中间体的制备方法
TW202033526A (zh) * 2018-12-07 2020-09-16 大陸商貝達藥業股份有限公司 用作酪胺酸激酶抑制劑的化合物、包含其的藥物組合物及其用途
AU2020242735B2 (en) 2019-03-19 2022-12-01 Central China Normal University Pyrazolopyrimidine compound, pharmaceutical composition, and application therefor
CN112979654B (zh) * 2019-12-16 2024-03-19 赛诺哈勃药业（成都）有限公司 杂芳基稠环化合物、其制备方法及应用
CN115551863A (zh) * 2020-06-11 2022-12-30 贝达药业股份有限公司 酪氨酸激酶抑制剂的盐型、晶型、药物组合物及其用途
CN111620881B (zh) * 2020-07-08 2023-03-31 浙江合聚生物医药有限公司 拉罗替尼衍生物及其制备方法和应用
CN113563343B (zh) * 2020-07-27 2022-05-24 杭州邦顺制药有限公司 取代的吡唑并[1,5-a]嘧啶化合物及其用途
CN112010860B (zh) * 2020-08-05 2023-03-10 南京纳丁菲医药科技有限公司 苄氧基吡唑并嘧啶化合物和药物组合物及其应用
CN114437075A (zh) * 2020-11-03 2022-05-06 上海瑶琪生物科技有限公司 用作ntrk激酶抑制剂的化合物及其应用
CN117751121A (zh) * 2021-07-30 2024-03-22 正大天晴药业集团股份有限公司 氨基吡唑并嘧啶化合物的晶体
WO2023011616A1 (zh) * 2021-08-06 2023-02-09 正大天晴药业集团股份有限公司 氨基吡唑并嘧啶化合物在治疗trk激酶介导的肿瘤中的用途
CN117088800B (zh) * 2023-08-18 2024-05-28 龙曦宁（上海）医药科技有限公司 一种5-甲基吡咯烷-3-醇盐酸盐的制备方法

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10356579A1 (de) 2003-12-04 2005-07-07 Merck Patent Gmbh Aminderivate
US8507488B2 (en) * 2008-05-13 2013-08-13 Irm Llc Fused nitrogen containing heterocycles and compositions thereof as kinase inhibitors
PE20110570A1 (es) 2008-07-01 2011-08-26 Genentech Inc Heterociclos biciclicos sustituidos
CN103965200B (zh) 2008-09-22 2016-06-08 阵列生物制药公司 作为trk激酶抑制剂的取代的咪唑并[1,2-b]哒嗪化合物
LT3372605T (lt) 2008-10-22 2022-02-10 Array Biopharma, Inc. Pakeistieji pirazolo[1,5-a]pirimidino junginiai, kaip trk kinazės inhibitoriai
AR077468A1 (es) * 2009-07-09 2011-08-31 Array Biopharma Inc Compuestos de pirazolo (1,5 -a) pirimidina sustituidos como inhibidores de trk- quinasa
WO2012034095A1 (en) * 2010-09-09 2012-03-15 Irm Llc Compounds and compositions as trk inhibitors
JP5959541B2 (ja) 2011-02-25 2016-08-02 ノバルティス アーゲー Ｔｒｋ阻害剤としてのピラゾロ［１，５−ａ］ピリジン
US9096605B2 (en) 2011-08-24 2015-08-04 Glaxosmithkline Llc Pyrazolopyrimidine derivatives as PI3 kinase inhibitors
CA2858958C (en) * 2011-12-12 2016-10-04 Dr. Reddy's Laboratories Ltd. Substituted pyrazolo[1,5-a]pyridine as tropomyosin receptor kinase (trk) inhibitors
SG11201506514QA (en) 2013-02-19 2015-09-29 Ono Pharmaceutical Co Trk-INHIBITING COMPOUND
US8969360B2 (en) 2013-03-15 2015-03-03 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of ATR kinase
CN104650092B (zh) * 2013-11-16 2017-11-10 广东东阳光药业有限公司 取代的杂芳基化合物及其组合物和用途
RU2687276C2 (ru) * 2013-12-06 2019-05-13 Вертекс Фармасьютикалз Инкорпорейтед Соединения, пригодные для использования в качестве ингибиторов atr киназы
KR102659741B1 (ko) * 2014-12-15 2024-04-23 주식회사 씨엠지제약 융합된 고리 헤테로아릴 화합물 및 trk 억제제로서의 이들의 용도

Also Published As

Publication number Publication date
CA3041942C (en) 2023-03-14
HUE057733T2 (hu) 2022-06-28
KR102616249B1 (ko) 2023-12-21
EP3533796A1 (en) 2019-09-04
KR20190067913A (ko) 2019-06-17
RU2019114600A3 (pt) 2021-02-20
ES2896943T3 (es) 2022-02-28
AU2017348826B2 (en) 2021-12-02
JP7046940B2 (ja) 2022-04-04
PL3533796T3 (pl) 2022-01-17
RU2764523C2 (ru) 2022-01-18
EP3533796B1 (en) 2021-09-29
CN109890820B (zh) 2020-11-03
WO2018077246A1 (zh) 2018-05-03
DK3533796T3 (da) 2021-11-08
PT3533796T (pt) 2021-11-18
EP3533796A4 (en) 2020-06-03
RU2019114600A (ru) 2020-11-30
CA3041942A1 (en) 2018-05-03
JP2019537588A (ja) 2019-12-26
AU2017348826A1 (en) 2019-05-23
BR112019008656A8 (pt) 2022-06-07
US10829492B2 (en) 2020-11-10
US20190352306A1 (en) 2019-11-21
CN109890820A (zh) 2019-06-14
MX2019004847A (es) 2019-08-29

Similar Documents

Publication Publication Date Title
BR112019008656A2 (pt) composto de aminopirazolopirimidina usado como inibidor de receptor de tirosina quinase de fator neurotrófico
BR112017003312A2 (pt) compostos de indazol como inibidores de fgfr quinase, preparação e uso dos mesmos
PH12018500041A1 (en) Substituted aza compoounds as irak-4 inhibitors
BR112018074621A2 (pt) derivados de pirazolopirimidina como inibidores de quinase
UY37124A (es) Nuevos compuestos de 6,7-dihidro-5h-benzo[7]anuleno sustituidos, procesos para su preparación y usos terapéuticos de los mismos
CR20160523A (es) Compuestos de imidazo[4,5-c]quinolin-2-ona y su uso para tratar cáncer
CU20160188A7 (es) Compuestos de indazole substituidos como inhibidores de irak4
EA201891024A1 (ru) Соединения-ингибиторы tank-связывающей киназы
BR112018010118A2 (pt) inibidores de cxcr2
EA202192151A1 (ru) Применение пиразолпиримидиновых производных для лечения нарушений, связанных с pi3k
SV2018005723A (es) Derivados de tiohidantoina substituidos como antagonistas del receptor de androgenos
CR20150633A (es) Derivados del bipirazol como inhibidores jak
UA111075C2 (uk) Триазолопіридинові сполуки як інгібітори кінази рім
EA201990833A1 (ru) Соединение пиридина
EA201792536A1 (ru) Триазоловые агонисты рецептора apj
CR20160496A (es) Inhibidores espirocíclicos sustituidos de la autotaxina
EA201690268A1 (ru) Замещенные производные хиназолин-4-она
NI201800042A (es) Nuevos derivados de pirrolo[2,3-d]pirimidina como inhibidores duales de dyrk1/clk1
UY35798A (es) Inhibidores del receptor del factor de crecimiento de fibroblastos
BR112018003634A8 (pt) Processo para preparar um inibidor parp, formas cristalinas e usos destes
EA201891626A1 (ru) Ингибиторы тирозинкиназы брутона
CL2016001409A1 (es) Inhibidores de quinasa relacionada con la tropomiosina (trk).
BR112016024936A2 (pt) moduladores de gpr40 à base de pirrolidina para tratamento de doenças como diabetes
NI201500115A (es) Estra-1,3,5(10), 16-tetraeno-3-carboxamidas para la inhibición de la 17b-hidroxiesteroide deshidrogenasa (akr1 c3)
BR112016027691A2 (pt) Composto de tetra-hidropiridopirimidina e seus usos

Legal Events

Date Code Title Description
B350 Update of information on the portal [chapter 15.35 patent gazette]
B06W Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette]